Hormone receptor-positive HER2-negative breast cancer (HR + BC) is the most prevalent BC characterized by estrogen or progesterone receptor (ER/PR) positive HER2-negative malignant cells comprised of about 60–70% of all BC [2,4]. This evidence concerns the gene NR4A1 and breast cancer.